The family of eight-year-old Tea, who suffers from Duchenne muscular dystrophy, is continuing a significant financial and medical battle following the rejection of funding by ZZZS. The specialized funding body declined to cover the cost of treatment utilizing the drug Elevidis in the United States. ZZZS reportedly determined that the therapy does not offer a realistic expectation of a cure or substantial improvement for a child of Tea’s age.
Consequently, the family has stated that voluntary donations represent the sole remaining avenue for pursuing treatment. To cover the necessary medical procedures, the family is currently seeking an additional one and a half million euros. The ongoing situation highlights the challenges faced by families managing rare and progressive genetic disorders.
The decision by ZZZS has shifted the focus entirely to private fundraising efforts to sustain the intensive care required for Tea. The continued appeal underscores the medical community’s and the family’s determination to secure the necessary resources to manage the progression of the rare condition.
Topics: #tea #zzzs #battle
